Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Not yet recruiting · NCT06273943 · Registry updated 2024-02-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. | Prevention | Not yet recruiting | Phase 3 | 2024-02-23 | NCT06273943 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ANRS, Emerging Infectious Diseases | 47 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hôpital Bichat | Paris | France | 1 |
| Hôpital Hôtel Dieu | Paris | France | 1 |
| Hôpital La Pitié Salpêtrière | Paris | France | 1 |
| Hôpital Lariboisière | Paris | France | 1 |
| Hôpital Necker | Paris | France | 1 |
| Hôpital Saint Antoine | Paris | France | 1 |
| Hôpital Saint Louis | Paris | France | 4 |
| Hôpital Tenon | Paris | France | 4 |